Synergistic effects of gemcitabine and gefitinib in the treatment of head and neck carcinoma

Cancer Research

Volumn 66, Issue 2, 2006, Pages 981-988

  Chun, Patrick Y ^a   Feng, Felix Y ^a   Scheurer, Ashley M ^a   Davis, Mary A ^a   Lawrence, Theodore S ^a   Nyati, Mukesh K ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GEFITINIB; GEMCITABINE; GROWTH FACTOR RECEPTOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE;

ADVANCED CANCER; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CELL CYCLE S PHASE; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RADIATION RESPONSE; TUMOR GROWTH; TUMOR XENOGRAFT;

ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CELL CYCLE; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; HEAD AND NECK NEOPLASMS; HUMANS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR CELLS, CULTURED;

EID: 31544464043     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-2665     Document Type: Article

References (34)

1. Eisbruch A, Shewach DS, Bradford CR, et al. Radiation concurrent with gemcitabine for locally advanced head and neck cancer: a phase I trial and intracellular drug incorporation study. J Clin Oncol 2001;19:792-9.
2. Pignon JP, Bourhis J, Domenge C, Designe L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three metaanalyses of updated individual data. MACH-NC Collaborative Group. Meta-analysis of chemotherapy on head and neck cancer. Lancet 2000;355:949-55.
3. Eisbruch A, Lyden T, Bradford CR, et al. Objective assessment of swallowing dysfunction and aspiration after radiation concurrent with chemotherapy for head-and-neck cancer. Int J Radiat Oncol Biol Phys 2002;53: 23-8.
4. Suntharalingam M. The role of concurrent chemotherapy and radiation in the management of patients with squamous cell carcinomas of the head and neck. Semin Oncol 2003;30:37-45.
5. Huncharek M, Kupelnick B. Combined chemoradiation versus radiation therapy alone in locally advanced nasopharyngeal carcinoma: results of a meta-analysis of 1,528 patients from six randomized trials. Am J Clin Oncol 2002;25:219-23.
6. Zackrisson B, Mercke C, Strander H, Wennerberg J, Cavallin-Stahl E. A systematic overview of radiation therapy effects in head and neck cancer. Acta Oncol 2003;42:443-61.
7. O-charoenrat P, Rhys-Evans PH, Modjtahedi H, Eccles SA. The role of c-erbB receptors and ligands in head and neck squamous cell carcinoma. Oral Oncol 2002; 38:627-40.
8. Santini J, Formento JL, Francoual M, et al. Characterization, quantification, and potential clinical value of the epidermal growth factor receptor in head and neck squamous cell carcinomas. Head Neck 1991;13:132-9.
9. Etienne MC, Pivot X, Formento JL, et al. A multifactorial approach including tumoural epidermal growth factor receptor, p53, thymidylate synthase and dihydropyrimidine dehydrogenase to predict treatment outcome in head and neck cancer patients receiving 5-fluorouracil. Br J Cancer 1999;79:1864-9.
10. Bonner JA, Giralt J, Harari PM, et al. Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: a phase III study of high dose radiation therapy with or without cetuximab. American Society of Clinical Oncology; 2004 June 5-8, 2004; New Orleans: Louisiana; 2004. p. 5507.
11. Nyati MK, Maheshwari D, Hanasoge S, et al. Radiosensitization by pan ErbB inhibitor CI-1033 in vitro and in vivo. Clin Cancer Res 2004;10:691-700.
12. Harari PM, Huang SM. Searching for reliablewfi epidermal growth factor receptor response predictors: commentary re M. K. Nyati et al., Radiosensitization by pan-ErbB inhibitor CI-1033 in vitro and in vivo. Clin Cancer Res 2004;10:691-700, 428-32.
13. Lawrence TS, Nyati MK. Small-molecule tyrosine kinase inhibitors as radiosensitizers. Semin Radiat Oncol 2002;12:33-6.
14. Ciardiello F, Caputo R, Bianco R, et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 2000;6:2053-63.
15. Giaccone G, Gonzalez-Larriba JL, van Oosterom AT, et al. Combination therapy with gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, gemcitabine and cisplatin in patients with advanced solid tumors. Ann Oncol 2004;15:831-8.
16. Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol 2004;22:777-84.
17. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003;290:2149-58.
18. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 2003;21:2237-46.
19. Dancey J. Epidermal growth factor receptor inhibitors in clinical development. Int J Radiat Oncol Biol Phys 2004;58:1003-7.
20. Douglass EC. Development of ZD1839 in colorectal cancer. Semin Oncol 2003;30:17-22.
21. Herbst RS. ZD1839: targeting the epidermal growth factor receptor in cancer therapy. Expert Opin Investig Drugs 2002;11:837-49.
22. Shewach DS, Lawrence TS. Gemcitabine and radio-sensitization in human tumor cells. Invest New Drugs 1996;14:257-63.
23. Fields MT, Eisbruch A, Normolle D, et al. Radiosensitization produced in vivo by once- vs. twice-weekly 2′2′-difluoro-2′-deoxycytidine (gemcitabine). Int J Radiât Oncol Biol Phys 2000;47:785-91.
24. Lawrence TS, Davis MA, Hough A, Rehemtulla A. The role of apoptosis in 2′,2′-difluoro-2′-deoxycytidine (gemcitabine)-mediated radiosensitization. Clin Cancer Res 2001;7:314-9.
25. McGinn CJ, Shewach DS, Lawrence TS. Radiosensitizing nucleosides. J Natl Cancer Inst 1996;88: 1193-203.
26. Di Gennaro E, Barbarino M, Bruzzese F, et al. Critical role of both p27KIP1 and p21CIP1/WAF1 in the antiproliferative effect of ZD1839 ("Iressa"), an epidermal growth factor receptor tyrosine kinase inhibitor, in head and neck squamous carcinoma cells. J Cell Physiol 2003;195:139-50.
27. Nelson JM, Fry DW. Akt, MAPK (Erk1/2), and p38 act in concert to promote apoptosis in response to ErbB receptor family inhibition. J Biol Chem 2001;276: 14842-7.
28. Morgan MA, Parsels LA, Parsels JD, Mesiwala AK, Maybaum J, Lawrence TS. Role of checkpoint kinase 1 in preventing premature mitosis in response to gemcitabine. Cancer Res 2005;65:6835-42.
29. Wang Z, Zhang B, Wang M, Carr BI. Cdc25A and ERK interaction: EGFR-independent ERK activation by a protein phosphatase Cdc25A inhibitor, compound 5. J Cell Physiol 2005;204:437-44.
30. Buchsbaum DJ, Bonner JA, Grizzle WE, et al. Treatment of pancreatic cancer xenografts with Erbitux (IMC-C225) anti-EGFR antibody, gemcitabine, and radiation. Int J Radiat Oncol Biol Phys 2002;54: 1180-93.
31. Bruns CJ, Harbison MT, Davis DW, et al. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin Cancer Res 2000;6: 1936-48.
32. Xiong HQ, Rosenberg A, LoBuglio A, et al. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial. J Clin Oncol 2004;22:2610-6.
33. Burris HA III, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403-13.
34. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib improves survival when added to gemcitabine in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group [NCIC-CTG]. Gastrointestinal Cancers Symposium (Meeting Abstracts) 2005; Abstract #77.